pc14586
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 29, 2020 (NCT04585750)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cellular tumor antigen p53ACTIVATOR
TP53 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06362642 | Phase 1 | Mar 28, 2024 | PMV Pharmaceuticals, Inc |
| NCT06054464 | Phase 1 | Sep 19, 2023 | PMV Pharmaceuticals, Inc |
| NCT05523687 | Phase 1 | Sep 6, 2022 | PMV Pharmaceuticals, Inc |
| NCT05249348 | Phase 1 | Dec 20, 2021 | PMV Pharmaceuticals, Inc |
| NCT04585750 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2020 | PMV Pharmaceuticals, Inc |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc | For profit | 5 | 5 | 2 | 2020 |
1 organizations
Page 1 / 1